Search results
Showing 1306 to 1320 of 7707 results
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Belimumab for treating lupus nephritis (terminated appraisal) (TA806)
NICE is unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. This is because GlaxoSmithKline did not provide an evidence submission.
Show all sections
Sections for TA806
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.